We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
-12.77%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$44.2B
AUM Growth
-$8.44B
(-16%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-0.68%
Top 10 Holdings %
Top 10 Hldgs %
14.01%
Holding
2,360
New
150
Increased
1,005
Reduced
998
Closed
187
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$209M |
| 2 |
CVS Health
CVS
|
+$195M |
| 3 |
Tyson Foods
TSN
|
+$136M |
| 4 |
ExxonMobil
XOM
|
+$135M |
| 5 |
LyondellBasell Industries
LYB
|
+$130M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$239M |
| 2 |
Microsoft
MSFT
|
+$204M |
| 3 |
Johnson & Johnson
JNJ
|
+$157M |
| 4 |
Amazon
AMZN
|
+$144M |
| 5 |
Walmart Inc
WMT
|
+$137M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.23% |
| 2 | Healthcare | 16.49% |
| 3 | Financials | 11.74% |
| 4 | Industrials | 11.47% |
| 5 | Consumer Discretionary | 10.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TRHC
1626
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
| $596K | ﹤0.01% |
231,874
+92,257
| +66% | +$346K |
|
|
CNR
1627
DELISTED
Cornerstone Building Brands, Inc.
CNR
| $596K | ﹤0.01% |
24,354
-17,525
| -42% | -$427K |
|
|
SCWX
1628
DELISTED
SecureWorks Corp Class A Common Stock
SCWX
| $592K | ﹤0.01% |
54,512
-20,125
| -27% | -$229K |
|
1629
Cal-Maine
CALM
$3.87B
| $590K | ﹤0.01% |
+11,938
| New | +$606K |
|
1630
Interparfums
IPAR
$3.82B
| $587K | ﹤0.01% |
8,028
+2,438
| +44% | +$187K |
|
1631
Wingstop
WING
$3.15B
| $587K | ﹤0.01% |
7,869
-2,171
| -22% | -$189K |
|
1632
Ameresco
AMRC
$1.37B
| $585K | ﹤0.01% |
12,837
| – | – |
|
1633
Renasant Corp
RNST
$3.93B
| $583K | ﹤0.01% |
+20,228
| New | +$619K |
|
1634
Kontoor Brands
KTB
$4.24B
| $582K | ﹤0.01% |
17,452
-14,462
| -45% | -$562K |
|
1635
Costamare
CMRE
$1.7B
| $579K | ﹤0.01% |
47,890
+335
| +0.7% | +$4.66K |
|
|
TGH
1636
DELISTED
Textainer Group Holdings limited
TGH
| $579K | ﹤0.01% |
21,140
+1
| +0% | +$32 |
|
1637
Ooma
OOMA
$592M
| $578K | ﹤0.01% |
48,787
-27,583
| -36% | -$366K |
|
1638
Comstock Resources
CRK
$4.18B
| $576K | ﹤0.01% |
47,721
-102,675
| -68% | -$1.7M |
|
1639
Johnson Outdoors
JOUT
$497M
| $571K | ﹤0.01% |
9,339
-4,353
| -32% | -$301K |
|
1640
Vital Farms
VITL
$495M
| $566K | ﹤0.01% |
+64,665
| New | +$689K |
|
1641
Progress Software
PRGS
$1.79B
| $564K | ﹤0.01% |
12,444
-2,817
| -18% | -$134K |
|
1642
Babcock & Wilcox
BW
$1.55B
| $563K | ﹤0.01% |
93,389
-41,998
| -31% | -$294K |
|
1643
C4 Therapeutics
CCCC
$415M
| $563K | ﹤0.01% |
+74,729
| New | +$658K |
|
1644
Primoris Services
PRIM
$4.56B
| $561K | ﹤0.01% |
25,792
+7,889
| +44% | +$190K |
|
1645
Sturm, Ruger & Co
RGR
$599M
| $561K | ﹤0.01% |
8,812
-3,507
| -28% | -$236K |
|
1646
Evertec
EVTC
$1.78B
| $558K | ﹤0.01% |
15,125
+898
| +6% | +$34.3K |
|
1647
Miller Industries
MLR
$614M
| $556K | ﹤0.01% |
24,528
-451
| -2% | -$11.5K |
|
|
ARI
1648
Apollo Commercial Real Estate
ARI
$873M
| $552K | ﹤0.01% |
52,877
-8,661
| -14% | -$106K |
|
1649
Gentherm
THRM
$1.29B
| $551K | ﹤0.01% |
8,829
-5
| -0.1% | -$337 |
|
1650
Insmed
INSM
$29B
| $550K | ﹤0.01% |
27,879
-674
| -2% | -$14.1K |
|
Similar funds
VGA
AQR Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, AQR Capital Management held 2,360 positions worth $44.2B, down 16% from $52.7B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
AQR Capital Management's Q2 2022 filing shows 150 new, 1,005 increased, 998 reduced and 187 closed positions. Its largest new stake was Fluor: 339,891 shares worth $7.86M. The largest sale was Thermo Fisher Scientific, an estimated $239M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q2 2022 buy was Fluor: 339,891 shares worth $7.86M.
- AQR Capital Management added most to Gilead Sciences in Q2 2022, an estimated $209M increase.
- AQR Capital Management's biggest Q2 2022 reduction was Thermo Fisher Scientific, cutting an estimated $239M.
- AQR Capital Management fully exited Roku in Q2 2022, selling an estimated $32.5M.
- AQR Capital Management's ten largest holdings make up 14% of its $44.2B portfolio in Q2 2022.
- AQR Capital Management opened 150 new positions and closed 187 in Q2 2022.
- AQR Capital Management's portfolio value fell 16% quarter-over-quarter to $44.2B.
Based on AQR Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.